# Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma

> **NCT03480672** · PHASE2 · COMPLETED · sponsor: **University of Leipzig** · enrollment: 211 (actual)

## Conditions studied

- HNSCC

## Interventions

- **DRUG:** Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
- **OTHER:** adjuvant radiochemotherapy

## Key facts

- **NCT ID:** NCT03480672
- **Lead sponsor:** University of Leipzig
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-06
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-01-30
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03480672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03480672, "Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03480672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*